Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn’s disease – one year follow up

References

• Löbermann M, Boršo D, Hilgendorf I, et al. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11:212–218.
   PubMed Web of Science ®Google Scholar
• Dart RJ, Irving PM. Optimising use of thiopurines in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:877–888.
   PubMed Web of Science ®Google Scholar
• Kantsø B, Simonsen J, Hoffmann S, et al. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977–2013. Am J Gastroenterol. 2015;110:1582–1587.
   PubMed Web of Science ®Google Scholar
• Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012;66:1177–1181.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066–1073.
   PubMed Web of Science ®Google Scholar
• Kantsø B, Halkjær SI, Thomsen OØ, et al. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn’s disease. Vaccine. 2015;33:5464–5469.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.
   PubMed Web of Science ®Google Scholar
• Lal G, Balmer P, Stanford E, et al. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods. 2005;296:135–147.
   PubMed Web of Science ®Google Scholar
• Pickering JW, Martins TB, Greer RW, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol. 2002;117:589–596.
   PubMed Web of Science ®Google Scholar
• Concepcion N, Frasch CE. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol. 1998;5:199–204.
   PubMedGoogle Scholar
• Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207–7211.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31:3585–3593.
   PubMed Web of Science ®Google Scholar
• Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55–70 years of age. Clin Infect Dis. 2009;49:241–248.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin Infect Dis. 2009;49:1318–1325.
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöele-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015–1023.
   PubMed Web of Science ®Google Scholar
• Lee CK, Kim HS, Ye BD, et al. Patients with Crohn’s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis. 2014;8:384–391.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042–1047.
   PubMed Web of Science ®Google Scholar
• Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148–154.
   PubMed Web of Science ®Google Scholar
• Nived P, Nagel J, Saxne T, et al. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017;35:3639–3646.
   PubMed Web of Science ®Google Scholar
• Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken). 2014;66:1016–1026.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004;33:283–288.
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:106–111.
   Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9:213–220.
   PubMedGoogle Scholar